Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd director and 10% owner Davidi Ishay reported multiple compensation-related option adjustments held by a trustee under the company’s 2011 Share Award Plan. The Form 4 shows paired acquisitions and dispositions of employee stock options, with 16 derivative transactions and no open‑market share purchases or sales.
The options cover blocks of 6,625 and 7,500 ordinary shares at exercise prices between $5.87 and $7.48, with expirations in 2026 and 2029. Footnotes state that exercise prices were adjusted for a cash dividend declared on March 11, 2026, and that vesting occurs in four equal annual installments from each grant date.
Kamada Ltd VP Regulatory Affairs Orit Pinchuk reported a series of employee stock option adjustments and grants held indirectly by a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, she was granted several blocks of 15,000 employee stock options each, with exercise prices of $5.87 and $7.25 per ordinary share and expirations extending to October 22, 2035. Matching dispositions of 15,000 options each back to the issuer at exercise prices of $6.12 and $7.50 were also reported. A footnote explains the exercise prices were adjusted under the 2011 Share Award Plan in connection with a cash dividend declared on March 11, 2026, with no other changes to the option terms, and that the options vest in four equal annual installments.
Kamada Ltd director David Tsur, through a trustee under the company’s 2011 Share Award Plan, reported a series of routine option award adjustments on Employee Stock Options (right to buy) linked to Ordinary Shares. The filing shows multiple grant acquisitions and matching dispositions back to the issuer at different exercise prices, leaving each award with 6,625 or 7,500 options outstanding per line. Exercise prices are stated in U.S. dollars as a convenience translation from NIS and were adjusted under the plan following a cash dividend declared by the board. The options vest in four equal annual installments from each grant date and carry expiration dates in 2026 and 2029.
Kamada Ltd VP of Plasma Operations Beladev Shavit reported routine employee stock option adjustments held through a trustee under the company’s 2011 Share Award Plan. The Form 4 shows five grants or awards and five matching dispositions to the issuer, each involving 15,000 options for Ordinary Shares.
Exercise prices, presented in U.S. dollars, range from $5.87 to $7.50 per share and were adjusted under the plan after a cash dividend declared on March 11, 2026. The options vest in four equal annual installments from the grant date and some series carry expiration dates as late as 2035.
KAMADA LTD VP of Operations Nir Eran reported compensation-related option adjustments held through a trustee under the company’s 2011 Share Award Plan. On April 7, 2026, he received grants of a total of 112,500 Employee Stock Options to buy Ordinary Shares and surrendered 112,500 options back to the company.
The grants include tranches of 22,500 options at exercise prices of $5.87 and $7.25 per share, with corresponding dispositions of 22,500 options at $6.12 and $7.50. Footnotes state exercise prices are translated from NIS and were adjusted under the 2011 Share Award Plan in connection with a cash dividend distribution, with all other award terms unchanged. The options vest in four equal annual installments starting on the grant date anniversaries and some tranches expire on August 28, 2028 while others expire on October 22, 2035.
Kamada Ltd VP Quality Yael Brenner reported compensation-related option adjustments rather than open‑market trades. On April 7, 2026, she was granted several tranches of employee stock options for 15,000 underlying ordinary shares, held indirectly by a trustee under the company’s 2011 Share Award Plan.
The filing shows paired entries where options with exercise prices of $6.12 and $7.50 were disposed of to the issuer and replaced with options at adjusted exercise prices of $5.87 and $7.25. A footnote explains the exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, with no other changes to award terms. The options vest in four equal annual installments.
Kamada Ltd. director Payorski Lilach reported administrative option changes involving employee stock options held by a trustee under the company’s 2011 Share Award Plan. The filing shows four grant/award acquisitions and four dispositions to the issuer, each for 7,500 options over Ordinary Shares.
The options carry exercise prices of $5.87 or $6.12 per share and expire on June 22, 2029. Footnotes state the exercise prices were adjusted under the plan following a cash dividend declared on March 11, 2026, and that all U.S. dollar exercise prices reflect a conversion from NIS. The options vest in four equal annual installments, with 25% vesting on each anniversary of the grant date.
Kamada Ltd. obtained a tax ruling from the Israel Tax Authority covering Israeli withholding tax on its previously announced cash dividend of $0.25 (approximately NIS 0.77) per share, totaling about $14.4 million.
Nazdaq shareholders who were on record as of March 23, 2026 and reside in tax treaty countries may qualify for a Reduced Withholding Tax Rate, and certain Israeli corporate holders may qualify for an exemption, if they follow the ruling’s procedures.
Kamada appointed IBI Trust Management as tax processing agent, and eligible Nasdaq shareholders must submit all required documentation by May 9, 2026 to benefit. The dividend is expected to be paid on April 7, 2026 and is not an indication of future dividends.
Kamada Ltd. reports that the U.S. FDA has approved its plasma collection center in San Antonio, Texas, following a February 2026 on-site inspection. The facility can support up to 50 donor beds and has a planned annual collection capacity of approximately 50,000 liters of normal source plasma at full capacity.
The San Antonio center is expected to generate annual revenues of $8 million to $10 million at full capacity and is anticipated to be one of the largest specialty plasma collection centers in the U.S. Together with existing sites in Houston and Beaumont, Kamada now operates three FDA-approved plasma centers in Texas and plans to seek European Medicines Agency approval for the San Antonio site.
Kamada Ltd director and 10% owner Davidi Ishay has filed an initial Form 3 detailing his ownership in the company. The filing reports indirect ownership of 22,084,287 Ordinary Shares held through controlled entities. It also lists several option grants over Ordinary Shares with exercise prices of 7.5200 and 6.1500 per share, expiring on September 25, 2026 and June 22, 2029. Each option grant covers either 6,625 or 7,500 underlying Ordinary Shares and is exercisable using a net-exercise method, with exercise prices translated from NIS to U.S. dollars based on a Bank of Israel exchange rate.